The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline

The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline

by Dale Bredesen

NOOK Book(eBook)

View All Available Formats & Editions

Available on Compatible NOOK Devices and the free NOOK Apps.
WANT A NOOK?  Explore Now


The instant New York Times and Wall Street Journal bestseller

A groundbreaking plan to prevent and reverse Alzheimer’s Disease that fundamentally changes how we understand cognitive decline.

Everyone knows someone who has survived cancer, but until now no one knows anyone who has survived Alzheimer's Disease. 
In this paradigm shifting book, Dale Bredesen, MD, offers real hope to anyone looking to prevent and even reverse Alzheimer's Disease and cognitive decline.  Revealing that AD is not one condition, as it is currently treated, but three, The End of Alzheimer’s outlines 36 metabolic factors (micronutrients, hormone levels, sleep) that can trigger "downsizing" in the brain. The protocol shows us how to rebalance these factors using lifestyle modifications like taking B12, eliminating gluten, or improving oral hygiene.
The results are impressive. Of the first ten patients on the protocol, nine displayed significant improvement with 3-6 months; since then the protocol has yielded similar results with hundreds more. Now, The End of Alzheimer’s brings new hope to a broad audience of patients, caregivers, physicians, and treatment centers with a fascinating look inside the science and a complete step-by-step plan that fundamentally changes how we treat and even think about AD.

Product Details

ISBN-13: 9780735216228
Publisher: Penguin Publishing Group
Publication date: 08/22/2017
Sold by: Penguin Group
Format: NOOK Book
Pages: 320
Sales rank: 596
File size: 5 MB

About the Author

Dale Bredesen, M.D., is internationally recognized as an expert in the mechanisms of neurodegenerative diseases such as Alzheimer’s disease. He graduated from Caltech, then earned his M.D. from Duke University Medical Center in Durham, North Carolina. He served as chief resident in neurology at the University of California, San Francisco (UCSF) before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH postdoctoral fellow. He held faculty positions at UCSF, UCLA, and the University of California, San Diego. Dr. Bredesen directed the Program on Aging at the Burnham Institute before coming to the Buck Institute in 1998 as its founding president and CEO. He is the chief medical officer of MPI Cognition.

Read an Excerpt

Meet Kristin.
Kristin was suicidal. Years before, she had watched in despair as her mother’s mind slipped away, forcing her to enter a nursing home after she could no longer recognize family members, let alone care for herself. Kristin had suffered along with her mother, who at the age of 62 had begun an 18‑year decline into Alzheimer’s disease. And at the end Kristin had suffered alone, for her mother was no longer sentient.
When Kristin was 65, she began to experience her own cognitive problems. She got lost when driving on the freeway, unable to remember where to get off and on, even on familiar routes. She could no longer analyze data critical to her job, or organize and prepare reports in a timely fashion. Unable to remember numbers, she had to write down even four digits, not to mention phone numbers. She had trouble remembering what she had read, and by the time she reached the bottom of a page had to start at the top again. Reluctantly, Kristin prepared her resignation. She began to make mistakes more and more frequently, often calling her pets by the wrong names and having to search to find the light switches in her own home, even though she had flipped them on and off for years.
Like many people, Kristin tried to ignore these symptoms. But they got worse and worse. After two years of unremitting cognitive decline, she consulted her physician, who told her she was becoming demented just as her mother had, and there was nothing he could do for her. He wrote “memory problems” on her chart, and because of that, she was unable to obtain long-term care insurance. She underwent retinal scanning, which revealed the Alzheimer’s-associated amyloid. She thought about the horror of watching her mother decline, about how she would live with progressive dementia and no long-term care, about the lack of treatment. She decided to commit suicide.
She called her best friend, Barbara, explaining, “I watched what my mother went through as she slipped away, and there is no way I will allow that to happen to me.” Barbara was horrified to hear Kristin’s saga. But unlike when other friends had fallen victim to dementia, this time Barbara had an idea. She told Kristin about new research she had heard about, and suggested that rather than ending her life, Kristin travel several thousand miles to the Buck Institute for Research on Aging, just north of San Francisco. In 2012, Kristin came to see me.
We talked for hours. I could offer her no guarantee, no example of any patient who had used the protocol—nothing more than diagrams, theory, and data from transgenic mice. In reality, Barbara had been premature in sending her to the Institute. And to make matters worse, the protocol I had developed had just been turned down for its first proposed clinical trial. The review board felt that it was “too complicated,” and pointed out that such trials are meant to test only a single drug or intervention, not an entire program (ah, if only diseases were that simple!). So all I could do was to go over the various parts of the protocol and recommend that she take these to her physician back home, asking him if he would work with her. She did that, and so began what has become the ReCODE protocol.
Three months later, Kristin called me at home on a Saturday to say she could not believe the changes in her mental abilities. She was able to work full-time again, to drive without getting lost, and to remember phone numbers without difficulty. She was feeling better than she had in years. When I put the phone down, what rushed into my mind were the decades of research, the countless hours at the whiteboard with lab members and colleagues, the arguments with myself about each detail of the theory and treatment approach. All of this had not been in vain; it had pointed us in the right direction. Of course Kristin was only one person—as they say, an “n of one”— and we needed to see similar results in thousands and ultimately in millions. I thought back to the doctor who told his patient, “You are just an anecdote; you are not statistically significant.” To which his patient replied, “Well, my family says that I am significant. Besides, I’m healthy once again, so I don’t care about statistics.” Indeed. Every fundamental change needs to start somewhere—every successful approach must start with Patient Zero—and Kristin was Patient Zero.

Table of Contents

Part 1 The Alzheimer's Solution

1 Disrupting Dementia 3

2 Patient Zero 21

3 How Does It Feel to Come Back from Dementia? 31

4 How to Give Yourself Alzheimer's: A Primer 41

Part 2 Deconstructing Alzheimer's

5 Wit's End: From Bedside to Bench and Back 55

6 The God Gene and The Three Types of Alzheimer's Disease 93

Part 3 Evaluation and Personalized Therapeutics

7 The "Cognoscopy"- Where Do You Stand? 115

8 ReCODE: Reversing Cognitive Decline 171

9 Success and the Social Network: Two People's Daily Routines 219

Part 4 Maximizing Success

10 Putting It All Together: You Can Do It 233

11 This Is Not Easy-Workarounds and Crutches 249

12 Resistance to Change: Machiavelli Meets Feynman 261

Appendices 275

Acknowledgments 291

Notes 295

Index 299

Customer Reviews

Most Helpful Customer Reviews

See All Customer Reviews

The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline 4.7 out of 5 based on 0 ratings. 3 reviews.
KCRWNYC_fanatic More than 1 year ago
I been waiting for this book for about 2 years now, every since I stumbled upon Dr. Bredesen's ground-breaking work at the Buck Institute for Aging (via a Cleveland Clinic or webinar, I believe) and his Aging papers. Both my parents, 79 and 81, suffer from varying degrees of dementia, and my father recently passed after hellish years of continued (but curiously not strictly linear) cognitive decline. While his death certificate says "Alzheimer's," he most certainly had a kind of metabolic dementia, probably a mix of the three types presented in this book: mostly Toxic, surely Cold/Atrophic and very likely Hot/Inflammatory. If only we had known of some of these tests 2-3 (or 10!) years ago. But also the trick and (huge) challenge is finding a physician and nursing team that is aware of this research and these revolutionary ideas. I can tell you that Bredesen's ideas have already begun to send shock waves throughout the medical community-- or at least that alert subset who make the effort both to continue their clinical education and to venture outside of classical medical school training. There will surely be those who dismiss his ideas, but they makes so much sense to me (as well as to alot of folks much smarter than I) and offer both affordable and immediately applicable therapeutic interventions unlike any other research or reasoning in this field in my lifetime. Bredesen is the first I know of to (A) challenge the prevailing (I would say clearly fallacious/misguided) understanding of Alzheimer's (and dementias generally) and also (B) sub-categorize different presentations in a way that opens up never before considered avenues for treatment. In this regard, he approaches this disease much the way we in Traditional Chinese Medicine (and other systems medicine folks, as those working in Functional (also called Restorative or Nutritional) Medicine) do: piecing together characteristics of a clinical presentation that suggest an archetype or pattern and, rather than asking, "What disease does this person have?" asking instead, "What kind of person (or, more specifically here, physiology) has this disease?" Because it's so packed with mind blowing information, the book can be a bit of slog at times-- even compared to similar titles that have come out this year like unDoctored (William Davis), The Plant Paradox (Steven Gundry) and Head Strong (Dave Asprey)-- but mostly this only reflects the extent of Dr. Bredesen's research and intellect. I am hoping, though, that the publisher or author will come out with a more approachable "highlights" summary as has been done with similar titles. (And maybe add summary tables for Type 1 (Inflammatory) and 2 (Atrophic) presentations the way they've done for Type 3 (Toxic).) Without a question this book is worth the effort for anyone touched by someone experiencing or at risk for (pretty much everyone) cognitive decline. From what I can tell, Bredesen's approach applies broadly to any and all dementias be they officially diagnosed as Alzheimer's or not. Please correct me, someone, if I am wrong. I hope to update this review as I continue to analyze and re-read this work-- and encourage conversations among clinicians and the public. I imagine Dr. Bredesen or his publisher will provide or has provided a venue for such.
Anonymous More than 1 year ago
I believe and his Aging papers. and Take a Barnes $10 Off coupons code from
Anonymous More than 1 year ago
If you want to know about dementia, and what can be done about it, get this book & digest it